Displaying 41–50 of 588 results
Feb 22, 2021 Beacon Stories
Charity’s recent rapid decline in vision due to RP and her daughter’s diagnosis with RP has caused her to open up about her vision loss journey. After getting involved with the Foundation, Charity now feels like she has a voice to help others in the visually impaired community.
Feb 17, 2021 Eye On the Cure Research News
His latest Foundation grant is helping move the drug toward a clinical trial
Feb 11, 2021 Eye On the Cure Research News
Therapy developers use the My Retina Tracker Registry to recruit for human studies of emerging therapies
Feb 8, 2021 Beacon Stories
Diagnosed with retinitis pigmentosa at a very young age, growing up, Erin never let her progressive vision loss stop her from keeping up with her friends and siblings. Throughout the 1990s, Erin was featured in several Foundation Fighting Blindness campaigns to raise funds for retinal research. Today, 34-year-old Erin is resilient as ever, still hopeful research will one day find her a cure.
Feb 4, 2021 The Foundation in the News
Former Spark Therapeutics head of ophthalmic medical affairs, responsible for the development and approval of Luxturna™, to lead development of SparingVision’s proprietary asset, SPVN06, and further pipeline development
Feb 3, 2021 Insights Forum
The Foundation Fighting Blindness is pleased to provide a recording and full transcript of the Insights Forum, our quarterly conference call providing updates to the inherited retinal disease community. The call took place on January 29, 2021.
Feb 2, 2021 Eye On the Cure Research News
Researchers believe the VLC-PUFAs may benefit people with autosomal dominant Stargardt disease, AMD, and possibly other retinal degenerations
Jan 29, 2021 The Foundation in the News
Development of lead asset SPVN06 to further benefit from high-level Clinical Advisory Board
Jan 28, 2021 Eye On the Cure Research News
The company plans to enroll additional patients as young as four years old
Jan 26, 2021 Eye On the Cure Research News
Company will seek marketing approval for the emerging therapy